These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19159461)

  • 21. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.
    Chou S; Van Wechel LC; Marousek GI
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2557-9. PubMed ID: 16801445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress.
    Hamirally S; Kamil JP; Ndassa-Colday YM; Lin AJ; Jahng WJ; Baek MC; Noton S; Silva LA; Simpson-Holley M; Knipe DM; Golan DE; Marto JA; Coen DM
    PLoS Pathog; 2009 Jan; 5(1):e1000275. PubMed ID: 19165338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.
    Iwahori S; Umaña AC; VanDeusen HR; Kalejta RF
    J Biol Chem; 2017 Apr; 292(16):6583-6599. PubMed ID: 28289097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.
    Gershburg E; Hong K; Pagano JS
    Antimicrob Agents Chemother; 2004 May; 48(5):1900-3. PubMed ID: 15105156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
    Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
    J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ULb' region of the human cytomegalovirus genome confers an increased requirement for the viral protein kinase UL97.
    Wang D; Li G; Schauflinger M; Nguyen CC; Hall ED; Yurochko AD; von Einem J; Kamil JP
    J Virol; 2013 Jun; 87(11):6359-76. PubMed ID: 23536674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
    Chou S; Wu J; Song K; Bo T
    Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase.
    Krosky PM; Baek MC; Jahng WJ; Barrera I; Harvey RJ; Biron KK; Coen DM; Sethna PB
    J Virol; 2003 Jul; 77(14):7720-7. PubMed ID: 12829811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.
    Hume AJ; Finkel JS; Kamil JP; Coen DM; Culbertson MR; Kalejta RF
    Science; 2008 May; 320(5877):797-9. PubMed ID: 18467589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.
    Marschall M; Stein-Gerlach M; Freitag M; Kupfer R; van den Bogaard M; Stamminger T
    J Gen Virol; 2001 Jun; 82(Pt 6):1439-1450. PubMed ID: 11369889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.
    Kamil JP; Hume AJ; Jurak I; Münger K; Kalejta RF; Coen DM
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16823-8. PubMed ID: 19805380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.
    Reitsma JM; Savaryn JP; Faust K; Sato H; Halligan BD; Terhune SS
    Cell Host Microbe; 2011 Feb; 9(2):103-14. PubMed ID: 21320693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation.
    Sanchez Puch SI; Mathet VL; Porta M; Cuestas ML; Oubiña JR; Videla CM; Salomón HE
    Antiviral Res; 2009 Nov; 84(2):194-8. PubMed ID: 19712701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
    Chou S; Marousek GI
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory roles of protein kinases in cytomegalovirus replication.
    Marschall M; Feichtinger S; Milbradt J
    Adv Virus Res; 2011; 80():69-101. PubMed ID: 21762822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
    Reitsma JM; Terhune SS
    Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.
    Krosky PM; Baek MC; Coen DM
    J Virol; 2003 Jan; 77(2):905-14. PubMed ID: 12502806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.